drugset / Trial / NCT03876938
Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant based on previous study. However, data of combination of olanzapine and ondansetron is scarce.
Timeline
- Start
- 2019-03-01
- Primary completion
- 2020-08
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aprepitant | Other / unclassified | 80 mg | Oral |
| Subject | Olanzapine | Small molecule | 5 mg | Oral |
| Subject | Olanzapine | Small molecule | 10 mg | Oral |
| Background | Dexamethasone | Small molecule | 8 mg | Intravenous |
| Background | Ondansetron | Other / unclassified | 8 mg | Intravenous |
Indications
No indication recorded.